Home › NDC Lookup › RxCUI directory › RxCUI 790264

24 HR desvenlafaxine 100 MG Extended Release Oral Tablet — RxCUI 790264

RxNorm drug concept · Semantic clinical drug
RxCUI 790264 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 8 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI790264
Official name24 HR desvenlafaxine 100 MG Extended Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asdesvenlafaxine 100 MG 24HR Extended Release Oral Tablet
FDA products mapped4
Package NDCs mapped8
Reported Medicaid activity (SDUD)14,227 prescriptions · 39 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Desvenlafaxine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Desvenlafaxine is an antidepressant approved for adults with major depressive disorder (MDD). It belongs to a class called SNRIs — drugs that help keep more of two brain chemicals,...
  • What is desvenlafaxine actually used for?
  • Antidepressants like desvenlafaxine typically take time to work — it's not something you feel immediately. Clinical studies that showed effectiveness ran for about 8 weeks. Your pr...
  • How long will it take before I start feeling better?
📖 Read our full Desvenlafaxine guide →

🕸️ Concept Web — How 24 HR desvenlafaxine 100 MG Extended Release Ora... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 24 HR desvenlafaxine 100 MG Extended Release Oral Tablet RxCUI 790264

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Desvenlafaxine 734064
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Khedezla 1435475
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Desvenlafaxine Extended Release Oral Tablet 790263
    • Desvenlafaxine Oral Product 1154233
    • Desvenlafaxine Pill 1154234
    • Desvenlafaxine Extended Release Oral Tablet [Khedezla] 1435477
    • Khedezla Oral Product 1435478
    • Khedezla Pill 1435479
    • Extended Release Oral Tablet 316945
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Desvenlafaxine 100 MG 790262
    • 24 HR desvenlafaxine 100 MG Extended Release Oral Tablet [Khedezla] 1435480
    • Desvenlafaxine 100 MG [Khedezla] 1435476

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Desvenlafaxine 100 MG SCDC · 790262
  • Desvenlafaxine Extended Release Oral Tablet SCDF · 790263
  • Desvenlafaxine Oral Product SCDG · 1154233
  • Desvenlafaxine Pill SCDG · 1154234

Brand-Name Concepts

  • 24 HR desvenlafaxine 100 MG Extended Release Oral Tablet [Khedezla] SBD · 1435480
  • Desvenlafaxine 100 MG [Khedezla] SBDC · 1435476
  • Desvenlafaxine Extended Release Oral Tablet [Khedezla] SBDF · 1435477
  • Khedezla Oral Product SBDG · 1435478
  • Khedezla Pill SBDG · 1435479
  • Khedezla BN · 1435475

📦 FDA Products & Package NDCs

4 products · 8 package NDCs
8 package NDCs map to RxCUI 790264 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
46708-0152-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (46708-152-30) Desvenlafaxine Alembic Pharmaceuticals Limited 2013-03-05
46708-0152-90 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (46708-152-90) Desvenlafaxine Alembic Pharmaceuticals Limited 2013-03-05
46708-0153-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (46708-153-30) Desvenlafaxine Alembic Pharmaceuticals Limited 2013-03-05
46708-0153-90 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (46708-153-90) Desvenlafaxine Alembic Pharmaceuticals Limited 2013-03-05
63304-0191-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (63304-191-30) Desvenlafaxine Sun Pharmaceutical Industries, Inc. 2013-03-05
63304-0191-90 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (63304-191-90) Desvenlafaxine Sun Pharmaceutical Industries, Inc. 2013-03-05
63304-0192-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (63304-192-30) Desvenlafaxine Sun Pharmaceutical Industries, Inc. 2013-03-05
63304-0192-90 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (63304-192-90) Desvenlafaxine Sun Pharmaceutical Industries, Inc. 2013-03-05
Observed labelers: Alembic Pharmaceuticals Limited (4) · Sun Pharmaceutical Industries, Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.